Drug Interactions between Mysoline and remdesivir
This report displays the potential drug interactions for the following 2 drugs:
- Mysoline (primidone)
- remdesivir
Interactions between your drugs
primidone remdesivir
Applies to: Mysoline (primidone) and remdesivir
GENERALLY AVOID: Theoretical concerns exist that coadministration with potent inducers of CYP450 3A4 and/or P-glycoprotein (P-gp) may decrease the plasma concentrations of remdesivir, which has been shown in vitro to be a substrate of the metabolic isoenzyme and efflux transporter. However, no clinical interaction studies have been performed with remdesivir, and the overall potential for interactions is currently unknown. Remdesivir metabolism is thought to be mediated predominantly by hydrolases in vivo, which would not be significantly affected by CYP450 3A4 or P-gp inducers.
MANAGEMENT: Until more information is available, some experts recommend avoiding the concomitant use of remdesivir with potent CYP450 3A4 or P-gp inducers.
References
- Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
- Gilead Sciences, Inc "About Remdesivir. https://www.gilead.com/purpose/advancing-global-health/covid-19/about-remdesivir" (2020):
- European Medicines Agency "Summary on compassionate use. Remdesivir Gilead. https://www.ema.europa.eu/en/documents/other/summary-compassionate-use-remdesivir-gilead_en.pdf" (2020):
- US Food and Drug Administration "Fact sheet for health care providers emergency use authorization (EUA) of remdesivir (GS-5734TM) https://www.fda.gov/media/137566/download" (2020):
Drug and food interactions
primidone food
Applies to: Mysoline (primidone)
GENERALLY AVOID: Concurrent acute use of barbiturates and ethanol may result in additive CNS effects, including impaired coordination, sedation, and death. Tolerance of these agents may occur with chronic use. The mechanism is related to inhibition of microsomal enzymes acutely and induction of hepatic microsomal enzymes chronically.
MANAGEMENT: The combination of ethanol and barbiturates should be avoided.
References
- Gupta RC, Kofoed J "Toxological statistics for barbiturates, other sedatives, and tranquilizers in Ontario: a 10-year survey." Can Med Assoc J 94 (1966): 863-5
- Misra PS, Lefevre A, Ishii H, Rubin E, Lieber CS "Increase of ethanol, meprobamate and pentobarbital metabolism after chronic ethanol administration in man and in rats." Am J Med 51 (1971): 346-51
- Saario I, Linnoila M "Effect of subacute treatment with hypnotics, alone or in combination with alcohol, on psychomotor skills related to driving." Acta Pharmacol Toxicol (Copenh) 38 (1976): 382-92
- Stead AH, Moffat AC "Quantification of the interaction between barbiturates and alcohol and interpretation of fatal blood concentrations." Hum Toxicol 2 (1983): 5-14
- Seixas FA "Drug/alcohol interactions: avert potential dangers." Geriatrics 34 (1979): 89-102
Therapeutic duplication warnings
No warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
See also
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.